| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 03/13/2001 | CA2033937C Hemihydrate |
| 03/13/2001 | CA1341204C Analogues of igf-1 and igf-2 |
| 03/08/2001 | WO2001017211A2 Communications system |
| 03/08/2001 | WO2001016604A1 Screening for agents modulating tgf-beta cell signaling |
| 03/08/2001 | WO2001016365A1 Poly(ether-thioether), poly(ether-sulfoxide) and poly(ether-sulfone) nucleic acids |
| 03/08/2001 | WO2001016358A2 Method of screening for triacyglycerol hydrolase inhibitors |
| 03/08/2001 | WO2001016347A1 The hematopoietic, myeloprotecting, antitumor immune cells generating and radiosensitizing polysaccharide isolated from panax ginseng |
| 03/08/2001 | WO2001016331A1 Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression |
| 03/08/2001 | WO2001016330A2 Prevention of affections associated with porcine circovirus-2 |
| 03/08/2001 | WO2001016316A1 Novel g protein-coupled receptor protein and dna thereof |
| 03/08/2001 | WO2001016314A1 Iren protein, its preparation and use |
| 03/08/2001 | WO2001016312A2 Nucleic acid based modulators of gene expression |
| 03/08/2001 | WO2001016309A1 Novel g protein-coupled receptor protein and dna thereof |
| 03/08/2001 | WO2001016306A2 Chimeric antisense oligonucleotides and cell transfecting formulations thereof |
| 03/08/2001 | WO2001016304A2 Genetically engineered cell lines, and their uses, in particular for neurotoxicity testing |
| 03/08/2001 | WO2001016300A2 Method of identifying inhibitors of cdc25 |
| 03/08/2001 | WO2001016296A2 Use of cytokines, cells, and mitogens to inhibit graft versus host disease |
| 03/08/2001 | WO2001016293A2 Dna encoding the human serine protease t |
| 03/08/2001 | WO2001016290A2 Dna encoding the human serine protease eos |
| 03/08/2001 | WO2001016289A2 Zymogen activation system |
| 03/08/2001 | WO2001016288A2 Dna encoding the human serine protease c-e |
| 03/08/2001 | WO2001016170A2 Card proteins involved in cell death regulation |
| 03/08/2001 | WO2001016165A2 Apoptin-associating protein |
| 03/08/2001 | WO2001016145A1 Immunopotentiating compositions |
| 03/08/2001 | WO2001016138A1 Sulfonylphenylpyrazole compounds useful as cox-2 inhibitors |
| 03/08/2001 | WO2001016136A2 Tricyclic inhibitors of poly(adp-ribose) polymerases |
| 03/08/2001 | WO2001016135A2 Reverse-turn mimetics and methods relating thereto |
| 03/08/2001 | WO2001016134A1 Selective antagonists of a2b adenosine receptors |
| 03/08/2001 | WO2001016133A2 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators |
| 03/08/2001 | WO2001016132A1 4,5-diaryloxazole compounds with prostaglandin 12 (pg12) agonistic activity |
| 03/08/2001 | WO2001016130A1 Substituted indolinones as tyrosine kinase inhibitors |
| 03/08/2001 | WO2001016128A1 Dibenzopyrans as glucocorticoid receptor antagonists for treatment of diabetes |
| 03/08/2001 | WO2001016120A1 Biaryl-oxa(thia)zole derivatives and their use as ppars modulators |
| 03/08/2001 | WO2001016114A2 Heterocyclic compounds and methods for modulating cxcr3 function |
| 03/08/2001 | WO2001016108A2 Bicyclic androgen and progesterone receptor modulator compounds and methods |
| 03/08/2001 | WO2001016106A1 Benzamide formulation with histone deacetylase inhibitor activity |
| 03/08/2001 | WO2001016105A1 4-substituted piperidine derivatives |
| 03/08/2001 | WO2001016104A1 Cyclopropylindole derivatives |
| 03/08/2001 | WO2001016103A1 Fused pyrrolecarboxamides: gaba brain receptor ligands |
| 03/08/2001 | WO2001016097A1 Phosphate mimics and methods of treatment using phosphatase inhibitors |
| 03/08/2001 | WO2001016096A2 Use of bis-sulfonamides for producing medicaments used for preventing or treating hyperlipidaemia |
| 03/08/2001 | WO2001016093A1 SUBSTITUTED α-HYDROXY ACID CASPASE INHIBITORS AND THE USE THEREOF |
| 03/08/2001 | WO2001016091A1 Biscyclopropanecarboxylic acid amide compounds and medicinal use thereof |
| 03/08/2001 | WO2001015745A1 Method and formula for tumor remission and suppression of cancer |
| 03/08/2001 | WO2001015740A1 Single-stranded oligodeoxynucleotide mutational vectors |
| 03/08/2001 | WO2001015737A2 Method for coupling molecules |
| 03/08/2001 | WO2001015733A2 Compositions for treating autoimmune disease containing a compounds which regulates icam-lfa-1 interaction and a compounds which regulates cd40-cd40 ligand interaction |
| 03/08/2001 | WO2001015730A1 DOSAGES FOR TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| 03/08/2001 | WO2001015726A2 Compositions for stimulating cytokine secretion and inducing an immune response |
| 03/08/2001 | WO2001015718A1 Extracts derived from pueraria mirifica, butea superba and/or mucuna collettii and extraction thereof |
| 03/08/2001 | WO2001015717A1 Brain cell or nerve cell protecting agents comprising ginseng |
| 03/08/2001 | WO2001015716A1 Plant extract mixtures and their uses |
| 03/08/2001 | WO2001015707A1 Uses of diterpenoid triepoxides as an anti-proliferative agent |
| 03/08/2001 | WO2001015694A1 Extended duration light activated cancer therapy |
| 03/08/2001 | WO2001015693A2 Treatment of migraine by the administration of alpha-lipoic acid or derivatives thereof |
| 03/08/2001 | WO2001015686A1 Selective cox-2 inhibitory novel esters from indolealkanols and novel amides from indolealkylamines |
| 03/08/2001 | WO2001015676A2 Compositions and methods for modulating hdl cholesterol and triglyceride levels |
| 03/08/2001 | WO2001015673A2 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure |
| 03/08/2001 | WO2001015664A2 Coformulation methods and their products |
| 03/08/2001 | WO2001015553A1 Dietary food supplement containing natural cyclooxygenase inhibitors |
| 03/08/2001 | WO2001015531A1 Methods of and compositions for inhibiting the proliferation of mammalian cells |
| 03/08/2001 | WO2000077184A9 Caspase-8 crystals, models and methods |
| 03/08/2001 | WO2000071094B1 Ascorbic acid derivative composition for increasing cell renewal rate |
| 03/08/2001 | WO2000066735A3 Human ion channel proteins |
| 03/08/2001 | WO2000062767A3 Pharmaceutical compositions containing pyridine or pyrimidine derivates for inhibition of cytokine production and secretion |
| 03/08/2001 | WO2000061624A8 48 human secreted proteins |
| 03/08/2001 | WO2000059506A8 HETEROCYCLIC CONTAINING BIPHENYL aP2 INHIBITORS AND METHOD |
| 03/08/2001 | WO2000059448A3 Association of no-synthase inhibitor(s) and metabolic antioxidant(s) |
| 03/08/2001 | WO2000057870A3 Viral treatment |
| 03/08/2001 | WO2000049137A3 Pluripotential cell derived from an embryonic stem cell and a nucleus of a somatic cell |
| 03/08/2001 | WO2000039283A8 Use of cd40 engagement to alter t cell receptor usage |
| 03/08/2001 | WO2000038786A3 Use of cyclooxygenase 2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia |
| 03/08/2001 | WO2000026246A9 Crystallized form of fc epsilon receptor alpha chain, its 3-d model and uses thereof |
| 03/08/2001 | WO1999065449A8 INHIBITORS OF TRANSCRIPTION FACTOR NF-λB |
| 03/08/2001 | WO1999064047A8 Novel antiviral compounds |
| 03/08/2001 | WO1999063930A8 Novel angiotensin receptor modulators and their uses |
| 03/08/2001 | WO1999019296A8 Aminobutanoic acid derivatives |
| 03/08/2001 | DE19942354A1 Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneimitteln Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and use in medicaments |
| 03/08/2001 | CA2417639A1 Isolation of natural l-.beta.-3-indolylalanine and enrichment of natural aliphatic amino acid mixtures with natural l-.beta.-3-indolylalanine |
| 03/08/2001 | CA2403243A1 Nucleic acid based modulators of gene expression |
| 03/08/2001 | CA2391868A1 Novel g protein-coupled receptor protein and dna thereof |
| 03/08/2001 | CA2391844A1 Method and formula for tumor remission and suppression of cancer |
| 03/08/2001 | CA2387711A1 Novel g protein-coupled receptor protein and dna thereof |
| 03/08/2001 | CA2387507A1 Communications system |
| 03/08/2001 | CA2387291A1 Dna encoding the human serine protease t |
| 03/08/2001 | CA2384435A1 Bicyclic androgen and progesterone receptor modulator compounds and methods |
| 03/08/2001 | CA2384126A1 Reverse-turn mimetics and methods relating thereto |
| 03/08/2001 | CA2383784A1 Apoptin-associating protein |
| 03/08/2001 | CA2383783A1 Use of bis-sulfonamides for producing medicaments used for preventing or treating hyperlipidaemia |
| 03/08/2001 | CA2383773A1 Methods and compositions for treating autoimmune disease |
| 03/08/2001 | CA2383693A1 Card proteins involved in cell death regulation |
| 03/08/2001 | CA2383606A1 Iren protein, its preparation and use |
| 03/08/2001 | CA2383603A1 Method of identifying inhibitors of cdc25 |
| 03/08/2001 | CA2383601A1 Dna encoding the human serine protease eos |
| 03/08/2001 | CA2383514A1 Screening for agents modulating tgf-beta cell signaling |
| 03/08/2001 | CA2383367A1 Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2 |
| 03/08/2001 | CA2383329A1 4,5-diaryloxazole compounds with prostaglandin 12 (pg12) agonistic activity |
| 03/08/2001 | CA2383002A1 Substituted .alpha.-hydroxy acid caspase inhibitors and the use thereof |
| 03/08/2001 | CA2382966A1 Biaryl-oxa(thia)zole derivatives and their use as ppars modulators |
| 03/08/2001 | CA2382961A1 Zymogen activation system |